Olmutinib

• Description:

  Olmutinib (HM61713; BI-1482694) is an orally active and irreversible third EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib is used for NSCLC[1][2].

• Product Name Alternative:

  HM61713; BI 1482694

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  EGFR

• Type:

  Reference compound

• Related Pathways:

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Olmutinib.html

• Purity:

  99.88

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  C=CC (NC1=CC=CC (OC2=C3C (C=CS3) =NC (NC4=CC=C (N5CCN (C) CC5) C=C4) =N2) =C1) =O

• Molecular Formula:

  C26H26N6O2S

• Molecular Weight:

  486.59

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Kim ES, et al. Olmutinib: First Global Approval. Drugs. 2016 Jul;76 (11) :1153-7.|[2]Mohamed W. Attwa, et al. Detection and characterization of olmutinib reactive metabolites by LC‐MS/MS: Elucidation of bioactivation pathways. Journal of Separation science. 18 November 2019.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  EGFR/ErbB1/HER1

• CAS Number:

  1353550-13-6